Reliance Genemedix withdraws European biosimilar EPO marketing application
This article was originally published in Scrip
Executive Summary
Reliance GeneMedix has withdrawn its application for marketing authorisation approval through the centralised procedure for its biosimilar Epostim (erythropoietin). The firm said in a statement that it had been unable to comply with a request from the European Medicines Agency for more information in the permitted time frame.